Discovery Series – SL GIP: Sublingual GLP Therapy

Presented by Jessica Gerhart, FNP, DC with Doug Yoch and Mike Kirkpatrick (Revelation Pharma)

The GLP-1 conversation has become impossible for any provider to ignore — but the injection-only model has left a lot of patients (and practices) looking for a better option. In this Discovery Series session, Jessica Gerhart, FNP, DC teams up with Doug Yoch and Mike Kirkpatrick from Revelation Pharma to introduce a sublingual approach that changes the math on adherence, cost, and clinical flexibility.

The session opens with a fast tour of the weight management landscape — where the GLP-1 category is heading, what patients are actually asking for, and where sublingual delivery fits alongside the injection-based programs your practice may already run. You’ll leave with a clear point of view on how to position both options in a patient conversation.

The clinical core is a deep look at the science behind sublingual GLP therapy: how the SNAC absorption enhancer works, what the pharmacokinetics look like compared to subcutaneous dosing, and — most importantly — the practical conversion tables for semaglutide (0.25–2.4 mg/week injection ↔ 2–12 mg/day sublingual) and tirzepatide (2.5–15 mg/week ↔ 3–16 mg/day). Your team will be able to convert a patient’s current regimen without a second-guess.

If you have patients who have plateaued, patients who cannot tolerate injections, or patients who have been priced out of the branded market, this session gives you a defensible clinical path forward and a program you can launch immediately.

This presentation is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Compounded medications are not FDA-approved and may differ from FDA-approved products in safety, quality, or effectiveness. All clinical decisions remain the sole responsibility of the prescribing healthcare provider. Individual results may vary.